At ACC 2017 the RE-CIRCUIT study was presented in the Late-Breaking Clinical Trials session. Here we have a series of Q&A videos presented by Dr. Hugh Calkins
Q&A 1: How do the absolute major bleeding event rates seen in RE-CIRCUIT for dabigatran etexilate and warfarin relate to those usually seen in clinical practice?
Q&A 2: What about the time pattern of the major bleeding events in the dabigatran etexilate and warfarin groups?
Q&A 3: In your opinion as an electrophysiologist, how could you interpret the differences in major bleeding events requiring medical attention and surgery?
Q&A 4: Did the time between the last dose of dabigatran and the start of the ablation procedure affect the occurrence of major bleeding events?
Q&A 5: With these results, would the availability of idarucizumab play a role in the decision of using dabigatran for ablation of atrial fibrillation?
Q&A 6: Are these results consistent with what we know about dabigatran etexilate?